Bungler, I don't know why anyone would expect some kind of good news at the CC. Maybe in the past, but not now.
Management needs to show us they have a way forward both clinically and financially. They need to show us they understand they cannot expect to raise money as easily as they have for the last few years. They need to show us how they will conserve cash.
I think they need to make a strong case for continuing Bavi development. Clearly they and we were wrong about Bavi-chemo in lung cancer. Didn't work well in liver or pancreas cancer either. Facts are facts.
Maybe Bavi will do well in breast cancer. Maybe Bavi-immunotherapies will work well. I'm not comfortable with "maybes" anymore.
If they can't make the case to continue Bavi, I'd like to see them bite the bullet and ax the drug development program in favor of mabufacturing with Avid.
This is no time to pretend Peregrine can go forward as in the past IMO.
Bungler, you are overlooking one big difference here, while otherwise your analysis is top on - I wrote about that pre-Q/CC UP phenomena a few days ago.
The big difference is the VOLUME. We have never seen 36Mil$ shares traded and if you want to confined that run up to last Friday, then 6+Mil shares neither.
But again, I do NOT imply that there is some big good news or other Q/CC event. I don't know, and probably only few do.
Market Data 
Markets 
AI
